The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation

  • Gouri Ranganathan
  • , Resat Unal
  • , Irina D. Pokrovskaya
  • , Preeti Tripathi
  • , Jerome I. Rotter
  • , Mark O. Goodarzi
  • , Philip A. Kern

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Objective: A common gain-of-function LPL variant, LPLS447X, has favorable clinical features and involves a C → G base change at nucleotide 1595 of the LPL cDNA, along with a haplotype, which includes other non-coding SNPs. The mechanism for the LPL gain-in-function is not clear. LPL translation is regulated by epinephrine by an RNA-protein complex, consisting of PKA subunits and an A kinase anchoring protein (AKAP), which targets the 3'UTR. Methods: To examine LPL translation of the LPLS447X variant, in vitro translation of LPL mRNA constructs was studied in the presence of cytoplasmic extracts from 3T3-F442A adipocytes treated with/without epinephrine. Results: When the C → G base change at nucleotide 1595 was introduced, LPL mRNA was less susceptible to inhibition by the adipocyte extract. Similarly, a lessened susceptibility to translation inhibition occurred when the complete haplotype was constructed in the full-length 3.6. kb LPL mRNA, when an irrelevant coding sequence was introduced into the LPL mRNA construct, and in response to the use of components of the RNA binding complex (PKA C and R subunits, and KH region of AKAP149). Conclusion: These studies suggest that the LPLS447X gain of function may be due to the base change in the LPL mRNA resulting in a decreased susceptibility to translational inhibition.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalAtherosclerosis
Volume221
Issue number1
DOIs
StatePublished - Mar 2012

Bibliographical note

Funding Information:
Grant support: Merit Review and REAP Grants (GR) from the Veterans Administration , and NIH Grants R37-DK039176 (PAK), R01-DK080327 (PAK), P01-HL060030 (W. Hsueh), R01-HL088457 (JIR), R01-DK079888 (MOG), M01-RR00425 , and UL1-RR033173 .

Funding

Grant support: Merit Review and REAP Grants (GR) from the Veterans Administration , and NIH Grants R37-DK039176 (PAK), R01-DK080327 (PAK), P01-HL060030 (W. Hsueh), R01-HL088457 (JIR), R01-DK079888 (MOG), M01-RR00425 , and UL1-RR033173 .

FundersFunder number
National Institutes of Health (NIH)R01-HL088457, P01-HL060030, R37-DK039176, UL1-RR033173, R01-DK080327, M01-RR00425
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney DiseasesR01DK079888
National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Veterans Affairs

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • A kinase anchoring protein
    • Cardiovascular disease
    • Epinephrine
    • Protein kinase A
    • Triglycerides

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation'. Together they form a unique fingerprint.

    Cite this